Alnylam screens cheaper on two of the three valuation measures provided, while Biogen has the lower price-to-book ratio. It’s a split comparison, not a clear verdict on value.
Biogen Inc. (BIIB) and Alnylam Pharmaceuticals Inc. (ALNY) are both in the health care sector, in the pharmaceuticals, biotechnology and life sciences industry. In the snapshot, their adjusted closing prices on 2026-10-30 were US$253.62 and US$165.00, respectively. But a lower share price doesn’t mean a stock is cheaper. The valuation multiples offer a more useful, though incomplete, comparison: Alnylam has the lower P/E and PEG, while Biogen has the lower P/B. None of these measures alone shows which stock offers better value.
Investor takeaway: Alnylam screens cheaper on P/E and PEG, while Biogen screens cheaper on P/B. The results are mixed, and these ratios don’t prove either stock is undervalued or predict future returns. Consider them alongside each company’s business, financial results and risks.
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
Biogen Inc
BIIB.US
Health Care
$253.62
$37.49B
1D
+1.59%
1W
+1.17%
Alnylam Pharmaceuticals Inc
ALNY.US
Health Care
$165.00
$22.10B
1D
-5.17%
1W
-26.35%
The valuation comparison is split: Alnylam leads on two multiples, Biogen on one
Alnylam’s P/E is 8.3, compared with Biogen’s 109.8. Its PEG is 0.21, versus Biogen’s 2.61. But Biogen’s P/B is 1.98, below Alnylam’s 6.13. Alnylam is cheaper on two of the three measures provided, but P/B points the other way.
Bull case
Alnylam’s P/E of 8.3 and PEG of 0.21 are both below Biogen’s figures of 109.8 and 2.61. The snapshot also lists Alnylam’s return on equity (ROE) over the trailing 12 months at 138.1%. These numbers may be worth investigating, but they don’t explain what’s driving earnings or show whether the valuation can last.
Bear case
Alnylam’s P/B of 6.13 is higher than Biogen’s 1.98, so it doesn’t look cheaper on every measure. Its reported trailing 12-month ROE of 138.1% also needs context. It shouldn’t be treated as a promise of future performance.
What the supplied multiples say
Alnylam’s P/E is 8.3, compared with Biogen’s 109.8. Its PEG of 0.21 is also below Biogen’s 2.61. Alnylam therefore screens cheaper on these two measures. The comparison flips on P/B: Biogen’s 1.98 is below Alnylam’s 6.13.
The results are mixed, even though Alnylam is cheaper on two of the three multiples provided. Each ratio measures a different aspect of valuation, and none proves that a stock is undervalued. For company details, see Biogen’s stock page and Alnylam’s stock page.
Company figures and what they leave open
The snapshot lists Biogen’s market capitalization at US$37.5 billion and its trailing 12-month ROE at 1.9%. Alnylam’s market capitalization is US$22.1 billion, with a trailing 12-month ROE of 138.1%. Both companies have a dividend yield of 0.00% and a Buy analyst consensus label in the supplied table. The listed analyst price targets are US$263.60 for Biogen and US$314.81 for Alnylam.
These are snapshot figures, not guarantees or a substitute for assessing each company’s prospects. The data doesn’t explain what’s driving the multiples, earnings or ROE. Don’t treat any single ratio or price target as a complete case for value.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
